Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults.

de Lange DW, Brüggemann RJM.

JAMA. 2020 Mar 10;323(10):997-998. doi: 10.1001/jama.2020.0172. No abstract available.

PMID:
32154852
2.

Implications for IV posaconazole dosing in the era of obesity.

Wasmann RE, Smit C, van Donselaar MH, van Dongen EPA, Wiezer RMJ, Verweij PE, Burger DM, Knibbe CAJ, Brüggemann RJM.

J Antimicrob Chemother. 2020 Apr 1;75(4):1006-1013. doi: 10.1093/jac/dkz546.

3.

Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B.

van de Peppel RJ, Schauwvlieghe A, Van Daele R, Spriet I, Van't Wout JW, Brüggemann RJ, Rijnders BJA, Hendriks BJC, de Boer MGJ.

Med Mycol. 2020 Jan 21. pii: myz134. doi: 10.1093/mmy/myz134. [Epub ahead of print]

PMID:
31965178
4.

Correction to: Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Nonobese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2020 Jan 9;37(2):32. doi: 10.1007/s11095-020-2756-7.

5.

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals.

Smit C, Wasmann RE, Goulooze SC, Wiezer MJ, van Dongen EPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Br J Clin Pharmacol. 2020 Feb;86(2):303-317. doi: 10.1111/bcp.14144. Epub 2020 Jan 7.

6.

High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Schauwvlieghe AFAD, Buil JB, Verweij PE, Hoek RAS, Cornelissen JJ, Blijlevens NMA, Henriet SSV, Rijnders BJA, Brüggemann RJM.

Mycoses. 2020 Feb;63(2):122-130. doi: 10.1111/myc.13028. Epub 2019 Dec 15.

7.

A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement.

Andrews LM, de Winter BCM, Cornelissen EAM, de Jong H, Hesselink DA, Schreuder MF, Brüggemann RJM, van Gelder T, Cransberg K.

Clin Pharmacokinet. 2019 Oct 26. doi: 10.1007/s40262-019-00831-8. [Epub ahead of print]

PMID:
31654367
8.

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.

Wasmann RE, Smit C, van Dongen EPH, Wiezer RMJ, Adler-Moore J, de Beer YM, Burger DM, Knibbe CAJ, Brüggemann RJM.

Clin Infect Dis. 2019 Sep 7. pii: ciz885. doi: 10.1093/cid/ciz885. [Epub ahead of print]

PMID:
31588493
9.

Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.

Hartman SJF, Brüggemann RJ, Orriëns L, Dia N, Schreuder MF, de Wildt SN.

Clin Pharmacokinet. 2020 Feb;59(2):173-205. doi: 10.1007/s40262-019-00813-w. Review.

10.

Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ.

Clin Infect Dis. 2019 May 2;68(Suppl 4):S244-S259. doi: 10.1093/cid/ciz064.

11.

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.

Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM.

Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076.

12.

Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine.

Wijma RA, Hoogtanders KEJ, Croes S, Mouton JW, Brüggemann RJM.

J Pharm Biomed Anal. 2019 Sep 10;174:161-167. doi: 10.1016/j.jpba.2019.05.054. Epub 2019 May 28.

PMID:
31170629
13.

ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children.

Warris A, Lehrnbecher T, Roilides E, Castagnola E, Brüggemann RJM, Groll AH.

Clin Microbiol Infect. 2019 Sep;25(9):1096-1113. doi: 10.1016/j.cmi.2019.05.019. Epub 2019 May 31.

PMID:
31158517
14.

Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2019 May 30;36(8):112. doi: 10.1007/s11095-019-2651-2. Erratum in: Pharm Res. 2020 Jan 9;37(2):32.

15.

Influenza Coinfection: Be(a)ware of Invasive Aspergillosis.

Verweij PE, Brüggemann RJM, Wauters J, Rijnders BJA, Chiller T, van de Veerdonk FL.

Clin Infect Dis. 2020 Jan 2;70(2):349-350. doi: 10.1093/cid/ciz391. No abstract available.

16.

A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.

Smit C, Wasmann RE, Goulooze SC, Hazebroek EJ, Van Dongen EPA, Burgers DMT, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Clin Pharmacokinet. 2019 Oct;58(10):1333-1343. doi: 10.1007/s40262-019-00762-4.

17.

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM.

PLoS One. 2019 Mar 21;14(3):e0213913. doi: 10.1371/journal.pone.0213913. eCollection 2019.

18.

The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study.

Huttner A, Wijma RA, Stewardson AJ, Olearo F, Von Dach E, Harbarth S, Brüggemann RJM, Mouton JW, Muller AE.

J Antimicrob Chemother. 2019 Jun 1;74(6):1656-1661. doi: 10.1093/jac/dkz095.

PMID:
30859184
19.

Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.

Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, Warris A, Koch BCP, Brüggemann RJ.

Med Mycol. 2019 Nov 1;57(8):937-943. doi: 10.1093/mmy/myz006.

PMID:
30759261
20.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8. Review.

21.

Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults.

Wasmann RE, Smit C, Ter Heine R, Koele SE, van Dongen EPH, Wiezer RMJ, Burger DM, Knibbe CAJ, Brüggemann RJM.

J Antimicrob Chemother. 2019 Apr 1;74(4):978-985. doi: 10.1093/jac/dky554.

PMID:
30649375
22.

Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report.

Bernts LHP, Wallenburg E, de Jonge HJM, Schaap B, Kusters R, Overtoom TTC, Brüggemann RJM, Drenth JPH, Lantinga MA.

J Antimicrob Chemother. 2019 Mar 1;74(3):829-830. doi: 10.1093/jac/dky456. No abstract available.

PMID:
30452619
23.

The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients.

Schijvens AM, van Hesteren FHS, Cornelissen EAM, Bootsma-Robroeks CMHHT, Brüggemann RJM, Burger DM, de Wildt SN, Schreuder MF, Ter Heine R.

Pediatr Nephrol. 2019 Mar;34(3):507-515. doi: 10.1007/s00467-018-4117-x. Epub 2018 Oct 30.

24.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.

Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.

PMID:
30137340
25.

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.

Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN).

J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230. doi: 10.1093/jac/dky286. Review.

PMID:
30085172
26.

Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Leenders EKSM, Westdorp H, Brüggemann RJ, Loeffen J, Kratz C, Burn J, Hoogerbrugge N, Jongmans MCJ.

Eur J Hum Genet. 2018 Oct;26(10):1417-1423. doi: 10.1038/s41431-018-0197-0. Epub 2018 Jun 14. Review.

27.

Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis.

Gustot T, Ter Heine R, Brauns E, Cotton F, Jacobs F, Brüggemann RJ.

J Antimicrob Chemother. 2018 Sep 1;73(9):2493-2496. doi: 10.1093/jac/dky189.

PMID:
29860319
28.

Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole.

Martial LC, van den Hombergh E, Tump C, Halmingh O, Burger DM, van Maarseveen EM, Brüggemann RJ, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 1;1089:16-23. doi: 10.1016/j.jchromb.2018.04.039. Epub 2018 Apr 27.

PMID:
29747155
29.

Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.

Vreugdenhil B, van der Velden WJFM, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, Blijlevens NMA, Brüggemann RJM.

Br J Clin Pharmacol. 2018 Sep;84(9):1980-1988. doi: 10.1111/bcp.13627. Epub 2018 Jun 19.

30.

Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults.

Wasmann RE, Ter Heine R, van Dongen EP, Burger DM, Lempers VJ, Knibbe CA, Brüggemann RJ.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00063-18. doi: 10.1128/AAC.00063-18. Print 2018 Jul.

31.

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduijn JK, Rijnders BJA.

Mycoses. 2018 Sep;61(9):656-664. doi: 10.1111/myc.12788. Epub 2018 Jul 13.

PMID:
29687483
32.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

33.

Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.

van den Boogaard M, Slooter AJC, Brüggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, Van der Voort PHJ, Houterman S, van der Hoeven JG, Pickkers P; REDUCE Study Investigators, van der Woude MCE, Besselink A, Hofstra LS, Spronk PE, van den Bergh W, Donker DW, Fuchs M, Karakus A, Koeman M, van Duijnhoven M, Hannink G.

JAMA. 2018 Feb 20;319(7):680-690. doi: 10.1001/jama.2018.0160. Erratum in: JAMA. 2018 Apr 10;319(14):1510.

34.

Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.

Smit C, De Hoogd S, Brüggemann RJM, Knibbe CAJ.

Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):275-285. doi: 10.1080/17425255.2018.1440287. Epub 2018 Feb 15. Review.

PMID:
29431542
35.

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer.

Willemsen AECAB, Knapen LM, de Beer YM, Brüggemann RJM, Croes S, van Herpen CML, van Erp NP.

Eur J Clin Pharmacol. 2018 Apr;74(4):465-471. doi: 10.1007/s00228-017-2394-0. Epub 2017 Dec 8.

36.

Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting.

Knapen LM, Beer Y, Brüggemann RJM, Stolk LM, Vries F, Tjan-Heijnen VCG, Erp NPV, Croes S.

J Pharm Biomed Anal. 2018 Feb 5;149:106-113. doi: 10.1016/j.jpba.2017.10.039. Epub 2017 Oct 29.

PMID:
29112898
37.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):263. doi: 10.1093/jac/dkx425. No abstract available.

PMID:
29112717
38.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):134-142. doi: 10.1093/jac/dkx354. Erratum in: J Antimicrob Chemother. 2018 Jan 1;73(1):263.

PMID:
29048485
39.

Itraconazole or Amphotericin B for Talaromycosis.

Brüggemann RJ, van de Veerdonk FL, Verweij PE.

N Engl J Med. 2017 Oct 5;377(14):1402-1403. doi: 10.1056/NEJMc1709123. No abstract available.

PMID:
28976857
40.

Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec.

41.

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Brüggemann RJ.

Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5. Review.

42.

Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.

Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Brüggemann RJM.

Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12751. Epub 2017 Sep 28. Review.

PMID:
28722255
43.

Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.

Muilwijk EW, Dekkers BGJ, Henriet SSV, Verweij PE, Witjes B, Lashof AMLO, Groeneveld GH, van der Hoeven J, Alffenaar JWC, Russel FGM, van de Veerdonk F, Brüggemann RJM.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00915-17. doi: 10.1128/AAC.00915-17. Print 2017 Sep.

44.

Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation.

Martial LC, Hoogtanders KEJ, Schreuder MF, Cornelissen EA, van der Heijden J, Joore MA, Van Maarseveen EM, Burger DM, Croes S, Brüggemann RJM, Aarnoutse RE.

Ther Drug Monit. 2017 Aug;39(4):412-421. doi: 10.1097/FTD.0000000000000422.

PMID:
28700522
45.

Early postnatal gentamicin and ceftazidime treatment in normal and food restricted neonatal wistar rats: Implications for kidney development.

Bueters RRG, Jeronimus-Klaasen A, Brüggemann RJM, van den Heuvel LP, Schreuder MF.

Birth Defects Res. 2017 Sep 1;109(15):1228-1235. doi: 10.1002/bdr2.1071. Epub 2017 Jul 11.

PMID:
28696058
46.

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.

Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Brüggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM.

Clin Pharmacokinet. 2018 Apr;57(4):475-489. doi: 10.1007/s40262-017-0567-8.

47.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
48.

Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.

Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann RJ, Wetzels J, van de Kar N, van den Heuvel L.

Clin Pharmacol Ther. 2017 Oct;102(4):671-678. doi: 10.1002/cpt.686. Epub 2017 May 26.

PMID:
28295239
49.

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.

Martial LC, Ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE, de Lange DW, Pickkers P, Brüggemann RJ.

Clin Pharmacokinet. 2017 Oct;56(10):1197-1206. doi: 10.1007/s40262-017-0509-5.

50.

Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring.

Martial LC, Aarnoutse RE, Mulder M, Schellekens A, Brüggemann RJM, Burger DM, Schene AH, Batalla A.

Eur Neuropsychopharmacol. 2017 Mar;27(3):205-216. doi: 10.1016/j.euroneuro.2017.01.009. Epub 2017 Jan 24. Review.

PMID:
28130001

Supplemental Content

Loading ...
Support Center